Reference : Intermittent bisphosphonate therapy in postmenopausal osteoporosis - Progress to date
Scientific journals : Article
Social & behavioral sciences, psychology : Sociology & social sciences
Human health sciences : Geriatrics
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/16587
Intermittent bisphosphonate therapy in postmenopausal osteoporosis - Progress to date
English
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Malaise, Olivier mailto [Université de Liège - ULg > > > Cert.ECG]
Neuprez, A. [> > > >]
Jouret, V. E. [> > > >]
Close, Pierre [Université de Liège - ULg > Département de pharmacie > Chimie médicale >]
2007
Drugs & Aging
Adis International Ltd
24
5
351-359
Yes (verified by ORBi)
International
1170-229X
Auckland
[en] Bisphosphonates are the most widely prescribed drugs in osteoporosis today. They have unequivocally shown their ability to reduce fracture rate at the spine (alendronic acid, risedronic acid, ibandronic acid) and at the hip (alendronic acid and risedronic acid). However, their dosage and administration procedures and the adverse reactions induced by their oral intake are responsible for low adherence. Therefore, intermittent regimens have been developed. Weekly alendronic acid and risedronic acid provide similar benefits, in terms of bone mineral density (BMD) and changes in biochemical markers, as those seen with their daily formulations. Ibandronic acid has been shown to reduce vertebral fractures when given intermittently. Ibandronic acid given orally monthly and intravenously every 2 or 3 months provides increases in BMD similar to the daily formulation. Yearly intravenous infusions of zoledronic acid are currently being evaluated for their ability to reduce fractures. If the efficacy and safety of bisphosphonates given at administration intervals longer than weekly are confirmed, this might significantly improve patient adherence and long-term outcomes of bisphosphonate treatment in postmenopausal osteoporosis.
http://hdl.handle.net/2268/16587

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Intermittent bisphosphonate therapy in postmenopau___[Drugs Aging_ 2007] - PubMed Result.htmNo commentaryPublisher postprint78.24 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.